Altre lingue PharmaEssentia Corporation

Azioni

6446

TW0006446008

Prezzo di chiusura Taiwan S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
285,5 ^TWD	-1,04%		0,00%	-17,49%

26/04	PharmaEssentia Corp. Presenta all'NMPA cinese il protocollo di studio clinico di Fase III di P1101 per la PMF pre-fibrotica/precoce o la PMF in fase avanzata con rischio da basso a intermedio-1	CI
24/04	PharmaEssentia Corp. annuncia la presentazione della domanda di autorizzazione all'immissione in commercio di BESREMi (Ropeginterferone alfa-2B) per il PV in Colombia	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	26/04
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	24/04
PharmaEssentia Corporation cancelled the transaction announced on April 2, 2024	16/04
PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	02/04
PharmaEssentia Corporation announced a financing transaction	02/04
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	28/03
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	04/03
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	04/03
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
PharmaEssentia Corporation(TWSE:6446) added to Taiwan TAIEX Index	19/02
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	24/01
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA	17/01
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft	02/11
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia	25/10/23
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate	03/10/23
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate	03/10/23
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on July 28, 2023.	28/09/23
PharmaEssentia Corporation's Equity Buyback announced on July 28, 2023, has closed with 4,000,000 shares, representing 1.19% for TWD 1,351.42 million	28/09/23
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China	20/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PharmaEssentia Corporation

Azioni

6446

TW0006446008

Altre lingue

Filtri